| P50 | author | Xuefei Huang | Q39185199 |
| P2093 | author name string | Dinesh Vyas | |
| | Marc D Basson | |
| | Mary F Walsh | |
| | Arpita K Vyas | |
| | Lakshmi S Chaturvedi | |
| | M El-Dakdouki | |
| | Nicolas Lopez-Hisijos | |
| | Sulakshana Gandhi | |
| P2860 | cites work | Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis | Q26858839 |
| | Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer | Q28291499 |
| | Molecular definition of breast tumor heterogeneity | Q28292256 |
| | Time for more optimism in metastatic breast cancer? | Q30354522 |
| | Assessing the in vivo efficacy of doxorubicin loaded hyaluronan nanoparticles | Q30570691 |
| | Development of drug loaded nanoparticles for tumor targeting. Part 1: Synthesis, characterization, and biological evaluation in 2D cell cultures | Q30607164 |
| | Tumor ablation with radio-frequency energy | Q30620718 |
| | Propofol's effects on phagocytosis, proliferation, nitrate production, and cytokine secretion in pressure-stimulated microglial cells | Q33450850 |
| | Synthesis and Characterization of Thermo-Sensitive Nanoparticles for Drug Delivery Applications | Q33595897 |
| | Multifunctional Stable and pH-Responsive Polymer Vesicles Formed by Heterofunctional Triblock Copolymer for Targeted Anticancer Drug Delivery and Ultrasensitive MR Imaging | Q33722416 |
| | Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapy | Q34023653 |
| | Early antibiotic administration but not antibody therapy directed against IL-6 improves survival in septic mice predicted to die on basis of high IL-6 levels. | Q34049911 |
| | Hormonal therapy of breast cancer | Q34054302 |
| | Development of Receptor Targeted Magnetic Iron Oxide Nanoparticles for Efficient Drug Delivery and Tumor Imaging | Q34069767 |
| | Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells | Q34200724 |
| | National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. | Q34299708 |
| | Autocrine IL-6 signaling: a key event in tumorigenesis? | Q34732166 |
| | The role of nitric oxide in cancer | Q35045661 |
| | Polyacrylic acid modified upconversion nanoparticles for simultaneous pH-triggered drug delivery and release imaging | Q35050793 |
| | Enhanced 4T1 breast carcinoma anticancer activity by co-delivery of doxorubicin and curcumin with core-shell drug-carrier based on heparin modified poly(L-lactide) grafted polyethylenimine cationic nanoparticles | Q35149949 |
| | Doxorubicin loaded pH-responsive micelles capable of rapid intracellular drug release for potential tumor therapy | Q35205959 |
| | Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor | Q35955367 |
| | Modulation of eIF5A expression using SNS01 nanoparticles inhibits NF-κB activity and tumor growth in murine models of multiple myeloma | Q36085366 |
| | NF-kappaB activation and interleukin 6 production in fibroblasts by estrogen receptor-negative breast cancer cell-derived interleukin 1alpha. | Q36501960 |
| | Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer | Q36509680 |
| | Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. | Q36536479 |
| | Inflammation and cancer: how hot is the link? | Q36556766 |
| | Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients | Q36649036 |
| | Neoadjuvant systemic therapy and the surgical management of breast cancer | Q36820261 |
| | Complications in breast surgery | Q36820270 |
| | Overview of adjuvant systemic therapy in early stage breast cancer | Q36820287 |
| | Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. | Q36900208 |
| | Population and target considerations for triple-negative breast cancer clinical trials | Q36914317 |
| | Neoadjuvant chemotherapy for "triple negative" breast cancer: a review of current practice and future outlook | Q37513837 |
| | Management of primary and advanced breast cancer in older unfit patients (medical treatment). | Q37599110 |
| | Triple negative breast cancers: clinical and prognostic implications. | Q37602289 |
| | Reporter genes: application to the study of mammalian gene transcription | Q37826420 |
| | Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy | Q37835104 |
| | Surface engineering of iron oxide nanoparticles for targeted cancer therapy. | Q37870178 |
| | Current treatment options in triple negative breast cancer | Q37903580 |
| | Radiation therapy. Recent advances and nursing implications | Q37921716 |
| | Understanding the dual nature of CD44 in breast cancer progression | Q37942289 |
| | Prognostic value of serum level of interleukin-6 and interleukin-8 in metastatic breast cancer patients. | Q53461351 |
| | Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma | Q56903494 |
| | Novel pH-Sensitive Micelles Generated by Star-Shape Copolymers Containing Zwitterionic Sulfobetaine for Efficient Cellular Internalization | Q61687047 |
| | Doxorubicin-Loaded Cyclic Peptide Nanotube Bundles Overcome Chemoresistance in Breast Cancer Cells | Q62677205 |
| | Adjuvant therapy in breast cancer | Q67244697 |
| | Daunorubicin cardiotoxicity: evidence for the importance of the quinone moiety in a free-radical-independent mechanism | Q73045056 |
| | Effects of combined conventional and modified ultrafiltration in adult patients | Q73580566 |
| | A practical guide to prescribing hormone replacement therapy | Q74777872 |
| | The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? | Q81768433 |
| | Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting | Q83165400 |
| | The prognostic value of triple negative in stage II/III breast cancer | Q83662713 |
| | Nanoparticles containing nitric oxide donor with antileishmanial agent for synergistic effect against visceral leishmaniasis | Q83839704 |
| | Conjugation of doxorubicin to cell penetrating peptides sensitizes human breast MDA-MB 231 cancer cells to endogenous TRAIL-induced apoptosis | Q84514602 |
| | A novel protein-based anticancer drug encapsulating nanosphere: apoferritin-doxorubicin complex | Q84525324 |
| | Current and proposed biomarkers of anthracycline cardiotoxicity in cancer: emerging opportunities in oxidative damage and autophagy | Q37980166 |
| | Dissecting the heterogeneity of triple-negative breast cancer | Q37997760 |
| | Neoadjuvant treatments for triple-negative breast cancer (TNBC). | Q38046580 |
| | Targeted approaches to triple-negative breast cancer: current practice and future directions | Q38070725 |
| | Relapsed triple-negative breast cancer: challenges and treatment strategies | Q38120666 |
| | Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation | Q38173683 |
| | Applications of nanomedicine in breast cancer detection, imaging, and therapy | Q38204453 |
| | Features of breast cancer in developing countries, examples from North-Africa | Q38207239 |
| | Surgical treatment of primary breast cancer in the neoadjuvant setting | Q38212607 |
| | Adjuvant chemotherapy in older women with breast cancer: who and what? | Q38215489 |
| | Chemotherapy response assay test and prognosis for breast cancer patients who have undergone anthracycline- and taxane-based chemotherapy | Q38465537 |
| | Effect of iontophoresis on topical delivery of doxorubicin-loaded solid lipid nanoparticles | Q38997576 |
| | Enhanced anticancer activity and circumvention of resistance mechanisms by novel polymeric/ phospholipidic nanocarriers of doxorubicin | Q38997579 |
| | Tea nanoparticles for immunostimulation and chemo-drug delivery in cancer treatment. | Q39002570 |
| | Antitumor efficacy of DMSA modified Fe3O4 magnetic nanoparticles combined with arsenic trioxide and adriamycin in Raji cells | Q39003541 |
| | Development of drug loaded nanoparticles for tumor targeting. Part 2: Enhancement of tumor penetration through receptor mediated transcytosis in 3D tumor models. | Q39172417 |
| | Temperature-sensitive polymer-coated magnetic nanoparticles as a potential drug delivery system for targeted therapy of thyroid cancer | Q39266980 |
| | The effects of silver nanoparticles and doxorubicin combination on DNA structure and its antiproliferative effect against T47D and MCF7 cell lines. | Q39266988 |
| | Folic acid protected silver nanocarriers for targeted drug delivery | Q39298452 |
| | Genistein inhibits MDA-MB-231 triple-negative breast cancer cell growth by inhibiting NF-κB activity via the Notch-1 pathway | Q39349283 |
| | Development of cationic solid lipid nanoparticles with factorial design-based studies for topical administration of doxorubicin. | Q39362380 |
| | Development of multifunctional hyaluronan-coated nanoparticles for imaging and drug delivery to cancer cells | Q39388913 |
| | Doxorubicin encapsulated nanocarriers for targeted delivery to estrogen responsive breast cancer | Q39560019 |
| | Chondroitin sulphate decorated nanoparticulate carriers of 5-fluorouracil: development and in vitro characterization. | Q39591847 |
| | Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia | Q39754914 |
| | Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. | Q39828317 |
| | Oxalate stimulates IL-6 production in HK-2 cells, a line of human renal proximal tubular epithelial cells | Q40398277 |
| | Nuclear factor kappa B (NF-kappa B), nuclear factor interleukin-6 (NFIL-6 or C/EBP beta) and nuclear factor interleukin-6 beta (NFIL6-beta or C/EBP delta) are not sufficient to activate the endogenous interleukin-6 gene in the human breast carcinoma | Q41180081 |
| | Hyaluronan binding by cell surface CD44. | Q41743967 |
| | Management of stage III breast cancer. | Q41749436 |
| | Effects of extracellular pressure and alcohol on the microglial response to inflammatory stimulation | Q42515745 |
| | Toxicity issues in cancer drug development. | Q43055933 |
| | Novel nanoparticles generated by polymeric amphiphiles with pi-pi conjugated small molecules for anti-tumor drug delivery | Q43804665 |
| | Surface functionalized gold nanoparticles for drug delivery. | Q43987066 |
| | Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer | Q44781880 |
| | Serum levels of tumor necrosis factor alpha correlate with response to neoadjuvant chemotherapy in locally advanced breast cancer. | Q44979729 |
| | Polyaspartic acid functionalized gold nanoparticles for tumor targeted doxorubicin delivery | Q45388867 |
| | Poly(ethylene glycol) versus dendrimer prodrug conjugates: influence of prodrug architecture in cellular uptake and transferrin mediated targeting | Q45719161 |
| | p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. | Q53428375 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | doxorubicin | Q18936 |
| | NF-κB | Q411114 |
| P304 | page(s) | 6413-6422 | |
| P577 | publication date | 2015-09-01 | |
| P1433 | published in | Journal of Nanoscience and Nanotechnology | Q2364336 |
| P1476 | title | Doxorubicin-Hyaluronan Conjugated Super-Paramagnetic Iron Oxide Nanoparticles (DOX-HA-SPION) Enhanced Cytoplasmic Uptake of Doxorubicin and Modulated Apoptosis, IL-6 Release and NF-kappaB Activity in Human MDA-MB-231 Breast Cancer Cells | |
| P478 | volume | 15 | |